Resistance
Early data from test-tube studies suggested that darunavir (Prezista) is active against HIV with high-level resistance to other protease inhibitors, and that resistance may develop more slowly than with other protease inhibitors[1].
A sub-analysis of the POWER studies has shown that eleven protease mutations are associated with a reduced response to darunavir, some of which have not been seen with other protease inhibitors. The major mutation seen in these studies was V32I, while mutations I54L/M and I47V were also common. The researchers believe that a number of mutations need to accumulate before a reduced response to the drug is seen[2].
There is little cross-resistance between darunavir and other protease inhibitors.
latest aidsmap news
- HIV prevalence may decline because the most vulnerable are infected and die first
- Lack of perceived need for HIV treatment associated with poor adherence
- TB doesn't always increase HIV viral load
- New 75mg darunavir tablet approved by FDA for use by HIV-positive children
- Thyroid checks recommended for people with HIV
- Knighthood for head of UK HIV charity
- Gay men often not accessing PEP despite risk of HIV exposure
- Inflammatory cytokines may contribute to endothelial dysfunction in people with untreated HIV
- Internalised homophobia leads to sexual risk taking by HIV-positive gay men
- Most gay men willing to consider PrEP for possible HIV exposure